Skip to main content
Evidence Snapshot

Telomerase reverse transcriptase

CHEMBL2916 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2916
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Telomerase reverse transcriptase as ChEMBL target CHEMBL2916, mapped to UniProt O14746. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Telomerase reverse transcriptase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2916
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O14746
Telomerase reverse transcriptase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Telomerase reverse transcriptase matters

As of 2026-09-13

Telomerase reverse transcriptase is reviewed as Telomerase reverse transcriptase (UniProt O14746); Telomerase reverse transcriptase shows approved-linked disease relevance led by anemia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 1242 compounds, and 380 assays, with lead potency reaching pChEMBL 9.2.

Disease context
anemia

Telomerase reverse transcriptase shows approved-linked disease relevance led by anemia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include IMETELSTAT SODIUM.

Start review with anemia because it currently carries approved-linked support. Linked drugs include IMETELSTAT SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 1242 compounds, and 380 assays for this target. The dominant activity type is IC50. CHEMBL443683 is the current potency anchor at pChEMBL 9.2.

Use CHEMBL443683 as the tractability anchor when discussing potency (pChEMBL 9.2).

Activity source · ChEMBL 36 via Core Engine
2 approved pChEMBL 9.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Telomerase reverse transcriptase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O14746, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why anemia is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1242
Total Compounds
380
Total Assays
2
Approved Drugs
IC50: 1012.0, EC50: 147.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL443683
 9.2 IC50 —
No preferred name
CHEMBL259739
 8.8 IC50 —
No preferred name
CHEMBL337762
 8.7 EC50 —
No preferred name
CHEMBL3347538
 8.3 IC50 —
No preferred name
CHEMBL3948172
 7.9 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:51:35Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2916